Form 4: TriSalus CFO Boosts Stake with Share Purchase

TriSalus Life Sciences' Chief Financial Officer, David Patience, acquired 3,657 shares of common stock at $4.10 per share.

Summary

• David Patience, Chief Financial Officer of TriSalus Life Sciences, Inc. (TLSI), purchased 3,657 shares of the company's common stock.
• The transaction occurred on February 23, 2026, at a price of $4.10 per share.
• Following this acquisition, Mr. Patience directly beneficially owns a total of 268,657 shares of TriSalus Life Sciences common stock.

Sentiment

Score: 7

Explanation: StockSavvy.ai views this as a moderately positive signal, as an insider's personal investment in company stock typically reflects confidence in its future performance and valuation.

Positives

• The Chief Financial Officer's purchase of company stock signals confidence in the company's future prospects and valuation.
• Insider buying can often be interpreted by the market as a positive indicator of management's belief in the company's intrinsic value.

Future Outlook

This filing does not contain any forward-looking statements or guidance regarding the company's future performance.

Industry Context

StockSavvy.ai notes that insider purchases, particularly by a Chief Financial Officer, are often closely watched by investors as they can provide insights into management's perception of the company's value and future trajectory within the competitive life sciences sector.

Related Party Transactions

• David Patience, the Chief Financial Officer, acquired 3,657 shares of TriSalus Life Sciences, Inc. common stock at $4.10 per share on February 23, 2026.

Stakeholder Impact

• Shareholders may view the CFO's stock purchase as a positive sign of management alignment and confidence in the company's prospects, potentially boosting investor sentiment.

Key Dates

Recommendation

The purchase of company stock by a key executive like the Chief Financial Officer, using personal capital, is a strong signal of confidence in the company's current valuation and future outlook. This insider buying suggests management believes the stock is undervalued or poised for growth, making it a positive indicator for potential investors.

Keywords

TriSalus Life Sciences, TLSI, Insider Trading, Form 4, David Patience, CFO, Stock Purchase, Beneficial Ownership, Biotechnology, Life Sciences